This morning, we published a new Quarterly Update on Bioniche Life Sciences Inc. (BNC-TSX; BNC-ASX). Bioniche is a Canadian company providing innovative research, technologies, and therapeutics for human and animal health worldwide. Bioniche is structured in three global business units: (1) Bioniche Therapeutics (Human Health); (2) Bioniche Animal Health; and (3) Bioniche Food Safety. The following key areas, among many other of Bioniche’s business initiatives, are profiled in this newest update, which is available free of charge on our website.

Last week, several companies within our coverage universe released financial results and corporate updates, including CEL-SCI Corporation (CVM-NYSE Amex), Pro-Pharmaceuticals Inc. (PRWP-OTC), and Advaxis Inc. (ADXS-OTC). In addition, Neuralstem, Inc. (CUR?-NYSE Amex)? announced a breakthrough in its clinical trials that it believes could greatly influence the treatment of amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease—a potentially fatal neuromuscular disorder.

Yesterday morning, Sanofi-Aventis SA (SNY-NYSE) released its 2010 financial results. Among other news, the company reported that emerging markets represented €9 billion in sales for the group, accounting for 29.9% of total sales and now representing the largest contributor to sales, by region. Sanofi-Aventis has previously reported an annual growth rate of 22.8% from 2005 to 2009 in emerging markets. In 2010, the company established Hangzhou Sanofi Minsheng Consumer Healthcare Co. in order to better access the consumer healthcare market in China. Currently, Sanofi-Aventis has three manufacturing facilities in Beijing, Hangzhou, and Shenzhen (Source: MedAdNews’ “Cardio Marketers Look East,” January 2011).

After market close today, Crystal Research published a business update on Unilife Corp. (UNIS-NASDAQ). Beyond covering Unilife’s recent significant news and progress under its Industrialization Agreement with sanofi-aventis SA (SNY-NYSE), the update also includes an early look at Unilife’s financials for the second quarter of FY 2011, ended December 31, 2010. This data comes from Unilife’s Appendix 4C for the three and six months ended December 31, 2010, filed on January 31, 2011, with the Australian Securities Exchange (ASX).